Calithera Announces Acceptance of Two Abstracts for Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annua...
October 01 2019 - 4:05PM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced that new data from its
research and development portfolio will be featured in two poster
presentations at the upcoming Society for Immunotherapy of Cancer
(SITC) 34th Annual Meeting 2019 in National Harbor, Maryland,
taking place November 6-10.
“The preclinical IL4I1 immuno-oncology program is an exciting
new addition to our pipeline, and we are pleased that initial data
from this program, as well as our ongoing CB-708 preclinical
program, have been accepted for presentation at this high-profile
meeting,” said Susan Molineaux, PhD, president and chief executive
officer of Calithera. “IL4I1 represents a novel target for cancer
immunotherapy and aligns with Calithera’s clinical focus on
onco-metabolism. The presentation of early-stage data from both the
IL4I1 and CB-708 programs demonstrate Calithera’s rigorous approach
to scientific exploration and support the further development of
these compounds, which we believe to have significant potential to
improve cancer treatment.”
Details of the poster presentations are as follows:
Title: |
|
Anti-tumor activity of a small molecule inhibitor of the
immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1
(IL4I1) |
Date: |
|
Friday, November 8, 2019 at 7:00 am-8:00 pm ET |
Abstract: |
|
P791 |
Title: |
|
CB-708, an orally bioavailable small molecule inhibitor
of CD73 with immunostimulatory and anti-tumor
activity |
Date: |
|
Saturday, November 9, 2019 at 7:00 am-8:30 pm ET |
Abstract: |
|
P484 |
Additional meeting information can be found at the SITC website
www.sitcancer.org. The poster presentation will be available at
www.calithera.com in the Publications Section.
About IL4I1
IL4I1 is an enzyme that is primarily expressed by tumor cells
and antigen presenting cells, and produces hydrogen peroxide, an
inhibitor of T-cell function. IL4I1 has a potential role in immune
evasion and decreases the ability of checkpoint therapy to mount an
anti-tumor immune response. Calithera’s pipeline includes an
investigational first-in-class, potent, orally available IL4I1
inhibitor.
About CB-708
CB-708 is a small molecule inhibitor of CD73, which is an enzyme
in the tumor microenvironment that produces adenosine, a powerful
inhibitor of immune function in tumors. CD73 is expressed across a
wide range of tumor types and tumor infiltrating leukocytes.
Expression of CD73 often correlates with poor prognosis in patients
with cancer. Blockade of adenosine production by CD73 inhibition is
expected to reverse immunosuppression in the tumor microenvironment
and enhance the immune system’s ability to fight the cancer.
CB-708 is orally bioavailable and shows distribution to all
tissues, including the brain.
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical
company pioneering the discovery and development of targeted
therapies that disrupt cellular metabolic pathways to
preferentially block tumor cells and enhance immune-cell activity.
Driven by a commitment to rigorous science and a passion for
improving the lives of people impacted by cancer and other
life-threatening diseases, Calithera is advancing a pipeline of
first-in-clinic, oral therapeutics to meaningfully expand treatment
options available to patients. Calithera is headquartered in South
San Francisco, California. For more information about Calithera,
please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the safety,
tolerability and efficacy of Calithera’s product candidates, the
overall advancement of Calithera’s product candidates in clinical
trials, the unmet need in the treatment of patients with advanced
disease, and Calithera’s plans to continue development of its
product candidates. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such
product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with
respect to any of the foregoing matters may have a negative effect
on Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found
in Calithera's most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, and other periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences,
Incorporated
CONTACT:
Jennifer McNealeyir@Calithera.com650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024